Discover investment opportunities in Biotech Small Cap Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Biotech Small Cap Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Biotech Small Cap Stocks using our Smart AI Filter.
7 stocks found for "Biotech Small Cap Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.34 | ±55.5% | -10.4 | 0.00% | |||
0.70 | ±46.8% | 1.5 | 0.00% | |||
1.01 | ±61.6% | -6.4 | 0.00% | |||
1.48 | ±64.6% | -7.4 | 0.00% | |||
1.43 | ±75.7% | -0.7 | 0.00% | |||
2.32 | ±96.8% | -0.7 | 0.00% | |||
2.18 | ±100.0% | -0.9 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
After reaching an important support level, Y-mAbs Therapeutics, Inc. (YMAB) could be a good stock pick from a technical perspective. YMAB recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Read moreWe are initiating coverage of Adaptimmune Therapeutics plc ADAP with a 12-month price target of $3.00, translating into sizeable upside from the stock's current price. Adaptimmune designs, develops, manufactures, and delivers innovative cell therapies via the company's unique T-cell receptor (TCR) platform to treat cancers across multiple solid tumor types.
Read moreQ: How do small cap biotech stocks like CRSP and MREO historically perform in volatile markets?
A: Small cap biotech stocks such as CRSP and MREO often experience significant volatility given their size and market sensitivity. Their performance is heavily influenced by regulatory news, clinical trial results, and market sentiment. Historically, these stocks can provide high returns but also carry high risks, especially in turbulent market conditions.
Q: What income potential do biotech stocks like SURF and ADMA offer to investors?
A: Biotech stocks like SURF and ADMA generally focus on reinvesting profits into research and development rather than dividend payouts. While these stocks may offer capital appreciation potential, they typically have low to no dividend income potential, making them less suitable for income-focused investors.
Q: In which economic cycles do small cap biotech stocks such as RCUS and FATE typically thrive?
A: Small cap biotech stocks like RCUS and FATE can thrive during periods of economic expansion when investor appetite for risk increases, leading to greater investment in innovative sectors. However, during economic downturns, investors may flee to safer assets, causing these stocks to underperform.
Q: What sector-specific risks should investors consider when evaluating biotech stocks like MRNS and KNSA?
A: Investors should consider regulatory risks, clinical trial dependency, intellectual property challenges, and funding capabilities when evaluating biotech stocks like MRNS and KNSA. These factors can lead to dramatic price swings based on trial outcomes or news events.
Q: How does the geographic focus of biotech firms impact their growth potential, specifically for companies like CERS and BNTC?
A: Geographic focus impacts growth potential as firms like CERS and BNTC expanding globally face market access challenges but also opportunities in emerging markets. Local regulatory environments and health care infrastructure significantly influence their market penetration and revenue growth.
Q: What are the competitive advantages of small cap biotech companies like CRSP in the current market?
A: Companies like CRSP hold competitive advantages through cutting-edge technologies, such as CRISPR gene editing, proprietary research, and strategic partnerships. Innovation and breakthrough therapies provide them leverage against larger biotech companies, fostering potential rapid growth.